Ailawadhi, S., Špička, I., Spencer, A., Lu, J., Oriol, A., Ling, S., Schjesvold, F., Berkovits, A., Hus, M., Li, C., Dimopoulos, M., Rajnics, P., Beşışık, S. K., Hungria, V., Custidiano, M. D. R., Parmar, G., Leleu, X., Li, F., Cerchione, C., Gomez, C., Ishida, T., Mateos, M. V., Buck, T. T., LeBlanc, R., Minarik, J., Goldschmidt, H., Zhang, R., Semiond, D., Suzan, F., Stefanova-Urena, M., Koch, V., Moreau, P. (2025). Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01767